Publication Name	World Journal of Clinical Oncology
Manuscript ID	104213
Country	United States

Received	2024-12-16 09:51
Peer-Review Started	2024-12-16 09:51
To Make the First Decision
Return for Revision	2025-01-03 09:49
Revised	2025-01-14 00:39
Second Decision	2025-01-15 02:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-01-15 11:34
Articles in Press	2025-01-15 11:34
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-02-06 01:52
Publish the Manuscript Online	2025-03-26 10:16

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Checkpoint kinase 1 as a promising target in colorectal cancer management
Manuscript Source	Invited Manuscript
All Author List	Wenxue Ma and Natalia Baran
Funding Agency and Grant Number
Corresponding Author	Wenxue Ma, MD, PhD, Professor, Department of Medicine, Sanford Stem Cell Institute, Moores Cancer Center, University of California San Diego, 2880 Torrey Pines Scenic Drive, MC 0695, La Jolla, CA 92093, United States. wma@health.ucsd.edu
Key Words	Colorectal cancer; Checkpoint kinase 1; Biomarker; Therapeutic target; Single-cell RNA sequencing; Nitidine chloride
Core Tip	This editorial highlights checkpoint kinase 1 (CHEK1) as a novel biomarker and therapeutic target in colorectal cancer (CRC). Pang et al demonstrate significant CHEK1 overexpression in CRC tissues using single-cell RNA sequencing, immunohistochemistry, and tissue microarray analyses. They identify nitidine chloride as a potent CHEK1 inhibitor that disrupts DNA damage repair, impairing tumor progression. These findings emphasize CHEK1's potential for improving CRC diagnosis and treatment while addressing research needs for clinical validation and tumor microenvironment exploration.
Publish Date	2025-03-26 10:16
Citation	<p>Ma W, Baran N. Checkpoint kinase 1 as a promising target in colorectal cancer management. <i>World J Clin Oncol</i> 2025; 16(4): 104213</p>
URL	https://www.wjgnet.com/2218-4333/full/v16/i4/104213.htm
DOI	https://dx.doi.org/10.5306/wjco.v16.i4.104213

Full Article (PDF)	WJCO-16-104213-with-cover.pdf
Manuscript File	104213_Auto_Edited_034812.docx
Answering Reviewers	104213-answering-reviewers.pdf
Audio Core Tip	104213-audio.m4a
Conflict-of-Interest Disclosure Form	104213-conflict-of-interest-statement.pdf
Copyright License Agreement	104213-copyright-assignment.pdf
Peer-review Report	104213-peer-reviews.pdf
Scientific Misconduct Check	104213-scientific-misconduct-check.png
Scientific Editor Work List	104213-scientific-editor-work-list.pdf
CrossCheck Report	104213-crosscheck-report.pdf